en · de · es · fr · pt
cjc-1295-notes.peptides9002.com › Guide › Background And Molecular Features — What the Evidence Shows

Background And Molecular Features — What the Evidence Shows

By Editorial Desk · published 2026-02-20 · last reviewed 2026-03-08 · Guide

drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Molecular Features

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Cjc-1295 at a glance

PropertyValueNotes
ClassSynthetic peptideGHRH receptor agonist
Sequence length29 amino acidsDerived from human GHRH
Molecular weightAbout 3368 Da without linkerAlbumin-binding form is heavier
AppearanceWhite to off-white lyophilized powderCommon form for research reference material
Typical storage-20 °C or below, desiccatedProtect powder from light and moisture

Identity and Naming History

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

Related pages on this site

Molecular Background and Naming

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 Background and Mechanism

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Reference notes

=== Stereoisomers === Since synephrine exists as either of two enantiomers (see: § Chemistry, below) which do not produce identical biological effects (see: § Pharmacology, below), some researchers have examined the stereoisomeric composition of synephrine extracted from natural sources. Although it seems clear that synephrine is found in those Citrus species which have been studied predominantly as the l-isomer, low levels of d-synephrine have been detected in juice and marmalade made from C. unshiu, and low levels (0.002%) have been reported in fresh fruit from C. aurantium. There are indications that some d-synephrine may be formed by the racemization of l-synephrine as a result of the processing of fresh fruit, although this matter has not been completely clarified. However, regardless of the situation in Citrus species, Ranieri and McLaughlin reported the isolation of racemic (i.e. a mixture of equal amounts of d- and l- stereoisomers) synephrine from a cactus of the genus Dolichothele, under conditions that would be unlikely to cause a significant amount of racemization.

Open Chess Championship Peter Bacanovic (1984), Martha Stewart's stockbroker; involved in the ImClone scandal Annie Duke (1987), professional poker player Greg Giraldo (1987), stand-up comedian Anna Ivey (1994), admissions counsellor Chubby Hubby or Aun Koh (1996), Singaporean food and travel blogger Emily Drabinski (1997), librarian and educator, president of the American Library Association Tinsley Mortimer (1999), socialite and television personality Chloe Arnold (2002), Internationally acclaimed tap dancer La Carmina (2005), alternative blogger on Gothic and Japanese pop culture Alison Desir (2007), activist, runner John Cochran (2009), winner of Survivor: Caramoan Leeza Mangaldas (2011), Indian podcaster and sex educator Sara Ali Khan (2016), daughter of Indian actor, director Saif Ali Khan and actress Amrita Singh

It also requires secondary dressing because wounds can quickly dry up with alginate dressing. Hydrofiber dressing: Made up of sodium carboxymethyl cellulose, hydrofibers can absorb high amounts of wound discharge, forming a gel and preventing skin maceration.

Sources: en.wikipedia.org

Notes from published material

These fractions also contained toxins readily separable from the short-chain isotoxin by preparative reverse-phase chromatography. Amino-acid sequencing of the first 28 residues indicated that both toxins were long-chain neurotoxins with identical N-termini. The LD50 of long-chain neurotoxins 2 from N. a. annulata and N. christyi venoms were 0.086 and 0.090 mg/kg, respectively. The venoms of these little-known elapids have some of the lowest intraperitoneal LD50 values of any African Naja species studied thus far, and have high concentrations of potent postsynaptic neurotoxins.

During World War II and the Cold War, the Hanford Site produced plutonium for U.S. nuclear weapons for more than 50 years. The plutonium for the first plutonium bomb, Fat Man, also came from there. Hanford is considered the most radioactively contaminated site in the Western Hemisphere. A total of 110,000 tons of nuclear fuel was produced there. In 1948, a radioactive cloud leaked from the plant. The amount of 131I alone was 5500 curies. Most of the reactors at Hanford were shut down in the 1960s, but no disposal or decontamination was done. After preliminary work, the world's largest decontamination operation began at Hanford in 2001 to safely dispose of the radioactive and toxic waste. In 2006, some 11,000 workers were still cleaning up contaminated buildings and soil to reduce radiation levels at the site to acceptable levels. This work is expected to continue until 2052. It is estimated that more than four million liters of radioactive liquid have leaked from storage tanks. It was only after the two superpowers agreed on a Partial Test Ban Treaty in 1963, which allowed only underground nuclear weapons testing, that the level of radioactivity in food began to decline. Shields Warren (1896-1980), one of the authors of a report on the effects of the atomic bombs dropped on Japan, was criticized for downplaying the effects of residual radiation in Hiroshima and Nagasaki, but later warned of the dangers of fallout. Fallout refers to the spread of radioactivity in the context of a given meteorological situation. A model experiment was conducted in 2008.

=== Equilibrium thermodynamics === When formed or re-equilibrated in reversible reactions, methane molecules can exchange isotopes with each other or with other substances present, such as H2O, H2 and CO2, and reach internal isotopic equilibrium. As a result, clumped isotopologues are enriched relative to the stochastic distribution.

=== More complex general models === When developing more detailed models for in-depth analysis, models are mostly generated for specific outbreak scenarios of specific diseases, including compartments for targeted research questions like hospitalization compartments or detection dynamics. Even though those models are often tailored for specific situations, there are complex models, still usable for a broad variety of different diseases. One of those attempts to create a general model includes twelve compartments, extending the well-known SEIR model by a second stage of infection, detection compartments, and two doses of vaccination. Additionally smear infections are incorporated via an external Pathogen

Sources: en.wikipedia.org

Further detail

== System components == A typical laboratory FPLC consist of one or two high-precision pumps, a control unit, a column, a detection system and a fraction collector. Although it is possible to operate the system manually, the components are normally linked to a personal computer or, in older units, a microcontroller.

== Structural Chemistry == Caricain is synthesized as a preproenzyme. There is evidence at the mRNA level for polymorphism, two very similar clones being isolated, one of which contained a C-terminal extension. The primary structure of the mature form of the enzyme has been determined, and is as predicted from one of the cDNA sequences. The protein is 216 amino acids in length, and is 68% identical in sequence to papain, 65% to chymopapain and 81% to glycyl endopeptidase. The three disulfide bonds are conserved between all the papaya proteinases, and there is no evidence for glycosylation. Caricain is an extremely basic protein, with pI estimated to be 11.7. The A280,1% is reported to be 18.3, giving a molar extinction coefficient of 4.193 104 M21 cm21. As with some other plant cysteine endopeptidases, caricain exhibits charge heterogeneity. This may be partly due to variation in the oxidization state of the active-site sulfur, as is the case with homologous enzymes from pineapple stem, although genetic polymorphism may also contribute. The crystal structure of caricain has been solved to a resolution of 1.8 A ̊, and demonstrates main-chain conformation very similar to that of papain. Caricain has four amino acid residues (Ser169-Lys172) not present in papain, but it is papain that is exceptional at this point in the sequence, showing a deletion not seen in other members of the family. The architecture of the active site of caricain is very similar to that of papain.

=== Hybrid techniques === Combinations of the above techniques produce a "hybrid" or "hyphenated" technique. Several examples are in popular use today and new hybrid techniques are under development. For example, gas chromatography-mass spectrometry, gas chromatography-infrared spectroscopy, liquid chromatography-mass spectrometry, liquid chromatography-NMR spectroscopy, liquid chromatography-infrared spectroscopy, and capillary electrophoresis-mass spectrometry. Hyphenated separation techniques refer to a combination of two (or more) techniques to detect and separate chemicals from solutions. Most often the other technique is some form of chromatography. Hyphenated techniques are widely used in chemistry and biochemistry. A slash is sometimes used instead of hyphen, especially if the name of one of the methods contains a hyphen itself.

Sources: en.wikipedia.org

Frequently asked questions

What is the difference between CJC-1295 and natural GHRH?

Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.

Why does one name cover two different peptides?

The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.

Is CJC-1295 a steroid or a natural hormone?

It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

Network